G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV
The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignan...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2003-07, Vol.32 (2), p.217-223 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 223 |
|---|---|
| container_issue | 2 |
| container_start_page | 217 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 32 |
| creator | REMBERGER, M NASEH, N ASCHAN, J BARKHOLT, L LEBLANC, K SVENNBERG, P RINGDEN, O |
| description | The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignancies were included. Conditioning consisted of total-body irradiation in 118 and busulphan in 37 patients. They were all given methotrexate combined with cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Of the 155 patients, 66 (43%) received G-CSF after HSCT. Those given G-CSF had a significantly shorter time to neutrophil engraftment (P |
| doi_str_mv | 10.1038/sj.bmt.1704108 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_589295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A182430801</galeid><sourcerecordid>A182430801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-a116d21e5c9cdac83261d8b096133c4872114008a10bdcaefb0fd1b6be53b0693</originalsourceid><addsrcrecordid>eNp1ksuO0zAUhiMEYsrAlh3IAsEuxbe4zrLqMG2lSiyA2VqOc9K6JHaJHdA8CO-Lo0YUpEFe2Dr6_nPzn2UvCZ4TzOSHcJxXXZyTBeYEy0fZjPCFyAsmisfZDFMhc8ZEeZU9C-GIMeEcF0-zK0Ilk1TKWfZrna8-36K9_QEO6SZCjw4aOh39yVuI1qAQoUMG2hbFXrtwarWLOlrv0BCs26PNbpnbGlxidYuCrdoxWnvn-4BsQDoEb6yOUKPokUYHuz-kKtaZUWUA-QZpM0RA67vNDdpu8-3d8-xJo9sAL6b7Ovt6-_HLapPvPq23q-UuN8WCx1wTImpKoDClqbWRjApSywqXgjBmuFxQQjjGUhNc1UZDU-GmJpWooGAVFiW7zvJz3vATTkOlTr3tdH-vvLZqCn1LL1CFLGlZJP7tmT_1_vsAIaqjH3qXWlRUcEoxEYIl6s1_qRFYcCwuqfa6BWVd49N6TWeDUUsiKWdYYpKo-QNUOjV01ngHjU3xfwTv_xIcQLfxEHw7jB8WHsxseh9CD82f4QlWo7VUOKpkLTVZKwleT1MNVQf1BZ-8lIB3E6BDskKT3GJsuHC8TAsqx_W8OnNOx6GHCzAV-g0Ujd7V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216637406</pqid></control><display><type>article</type><title>G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>REMBERGER, M ; NASEH, N ; ASCHAN, J ; BARKHOLT, L ; LEBLANC, K ; SVENNBERG, P ; RINGDEN, O</creator><creatorcontrib>REMBERGER, M ; NASEH, N ; ASCHAN, J ; BARKHOLT, L ; LEBLANC, K ; SVENNBERG, P ; RINGDEN, O</creatorcontrib><description>The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignancies were included. Conditioning consisted of total-body irradiation in 118 and busulphan in 37 patients. They were all given methotrexate combined with cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Of the 155 patients, 66 (43%) received G-CSF after HSCT. Those given G-CSF had a significantly shorter time to neutrophil engraftment (P <0.001). G-CSF treatment had no effect on erythrocyte transfusions, platelet engraftment and infections. However, patients treated with G-CSF had a significantly higher incidence of grades II-IV acute GVHD than those not given this treatment (34 vs 9%, P <0.001). The multivariate analysis showed that the effect of G-CSF was independent of other known risk factors for grades II-IV acute GVHD. Death from GVHD occurred in four and two cases (P=0.06) in the two groups, respectively. The cumulative incidences of transplant-related mortality, survival, chronic GVHD, relapse and relapse-free survival were similar in both groups. In conclusion, G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II-IV acute GVHD, but not transplant-related mortality.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1704108</identifier><identifier>PMID: 12838288</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Acute Disease ; Adolescent ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone marrow ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Busulfan ; Care and treatment ; Child ; Child, Preschool ; Colony-stimulating factor ; Cyclosporins ; Donors ; Erythrocytes ; Female ; Graft Survival - drug effects ; Graft versus host disease ; Graft versus host reaction ; Graft vs Host Disease - chemically induced ; Graft vs Host Disease - mortality ; Graft vs Host Disease - pathology ; Granulocyte colony-stimulating factor ; Granulocyte Colony-Stimulating Factor - adverse effects ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Health aspects ; Hematologic Neoplasms - complications ; Hematologic Neoplasms - mortality ; Hematologic Neoplasms - therapy ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - mortality ; Hematopoietic stem cells ; Histocompatibility antigen HLA ; HLA Antigens ; Humans ; Incidence ; Infant ; Irradiation ; Leukocytes (granulocytic) ; Leukocytes (neutrophilic) ; Male ; Medical sciences ; Methods ; Methotrexate ; Middle Aged ; Mortality ; Multivariate analysis ; Patients ; Physiological aspects ; Prophylaxis ; Radiation ; Retrospective Studies ; Risk analysis ; Risk factors ; Siblings ; Stem cell transplantation ; Stem cells ; Survival ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation, Homologous ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2003-07, Vol.32 (2), p.217-223</ispartof><rights>2003 INIST-CNRS</rights><rights>COPYRIGHT 2003 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jul 2, 2003</rights><rights>Nature Publishing Group 2003.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-a116d21e5c9cdac83261d8b096133c4872114008a10bdcaefb0fd1b6be53b0693</citedby><cites>FETCH-LOGICAL-c574t-a116d21e5c9cdac83261d8b096133c4872114008a10bdcaefb0fd1b6be53b0693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,2725,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14922093$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12838288$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1935756$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>REMBERGER, M</creatorcontrib><creatorcontrib>NASEH, N</creatorcontrib><creatorcontrib>ASCHAN, J</creatorcontrib><creatorcontrib>BARKHOLT, L</creatorcontrib><creatorcontrib>LEBLANC, K</creatorcontrib><creatorcontrib>SVENNBERG, P</creatorcontrib><creatorcontrib>RINGDEN, O</creatorcontrib><title>G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignancies were included. Conditioning consisted of total-body irradiation in 118 and busulphan in 37 patients. They were all given methotrexate combined with cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Of the 155 patients, 66 (43%) received G-CSF after HSCT. Those given G-CSF had a significantly shorter time to neutrophil engraftment (P <0.001). G-CSF treatment had no effect on erythrocyte transfusions, platelet engraftment and infections. However, patients treated with G-CSF had a significantly higher incidence of grades II-IV acute GVHD than those not given this treatment (34 vs 9%, P <0.001). The multivariate analysis showed that the effect of G-CSF was independent of other known risk factors for grades II-IV acute GVHD. Death from GVHD occurred in four and two cases (P=0.06) in the two groups, respectively. The cumulative incidences of transplant-related mortality, survival, chronic GVHD, relapse and relapse-free survival were similar in both groups. In conclusion, G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II-IV acute GVHD, but not transplant-related mortality.</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Busulfan</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Colony-stimulating factor</subject><subject>Cyclosporins</subject><subject>Donors</subject><subject>Erythrocytes</subject><subject>Female</subject><subject>Graft Survival - drug effects</subject><subject>Graft versus host disease</subject><subject>Graft versus host reaction</subject><subject>Graft vs Host Disease - chemically induced</subject><subject>Graft vs Host Disease - mortality</subject><subject>Graft vs Host Disease - pathology</subject><subject>Granulocyte colony-stimulating factor</subject><subject>Granulocyte Colony-Stimulating Factor - adverse effects</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Health aspects</subject><subject>Hematologic Neoplasms - complications</subject><subject>Hematologic Neoplasms - mortality</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - mortality</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA Antigens</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Irradiation</subject><subject>Leukocytes (granulocytic)</subject><subject>Leukocytes (neutrophilic)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methods</subject><subject>Methotrexate</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Prophylaxis</subject><subject>Radiation</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Siblings</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Survival</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation, Homologous</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ksuO0zAUhiMEYsrAlh3IAsEuxbe4zrLqMG2lSiyA2VqOc9K6JHaJHdA8CO-Lo0YUpEFe2Dr6_nPzn2UvCZ4TzOSHcJxXXZyTBeYEy0fZjPCFyAsmisfZDFMhc8ZEeZU9C-GIMeEcF0-zK0Ilk1TKWfZrna8-36K9_QEO6SZCjw4aOh39yVuI1qAQoUMG2hbFXrtwarWLOlrv0BCs26PNbpnbGlxidYuCrdoxWnvn-4BsQDoEb6yOUKPokUYHuz-kKtaZUWUA-QZpM0RA67vNDdpu8-3d8-xJo9sAL6b7Ovt6-_HLapPvPq23q-UuN8WCx1wTImpKoDClqbWRjApSywqXgjBmuFxQQjjGUhNc1UZDU-GmJpWooGAVFiW7zvJz3vATTkOlTr3tdH-vvLZqCn1LL1CFLGlZJP7tmT_1_vsAIaqjH3qXWlRUcEoxEYIl6s1_qRFYcCwuqfa6BWVd49N6TWeDUUsiKWdYYpKo-QNUOjV01ngHjU3xfwTv_xIcQLfxEHw7jB8WHsxseh9CD82f4QlWo7VUOKpkLTVZKwleT1MNVQf1BZ-8lIB3E6BDskKT3GJsuHC8TAsqx_W8OnNOx6GHCzAV-g0Ujd7V</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>REMBERGER, M</creator><creator>NASEH, N</creator><creator>ASCHAN, J</creator><creator>BARKHOLT, L</creator><creator>LEBLANC, K</creator><creator>SVENNBERG, P</creator><creator>RINGDEN, O</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20030701</creationdate><title>G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV</title><author>REMBERGER, M ; NASEH, N ; ASCHAN, J ; BARKHOLT, L ; LEBLANC, K ; SVENNBERG, P ; RINGDEN, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-a116d21e5c9cdac83261d8b096133c4872114008a10bdcaefb0fd1b6be53b0693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Busulfan</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Colony-stimulating factor</topic><topic>Cyclosporins</topic><topic>Donors</topic><topic>Erythrocytes</topic><topic>Female</topic><topic>Graft Survival - drug effects</topic><topic>Graft versus host disease</topic><topic>Graft versus host reaction</topic><topic>Graft vs Host Disease - chemically induced</topic><topic>Graft vs Host Disease - mortality</topic><topic>Graft vs Host Disease - pathology</topic><topic>Granulocyte colony-stimulating factor</topic><topic>Granulocyte Colony-Stimulating Factor - adverse effects</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Health aspects</topic><topic>Hematologic Neoplasms - complications</topic><topic>Hematologic Neoplasms - mortality</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - mortality</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA Antigens</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Irradiation</topic><topic>Leukocytes (granulocytic)</topic><topic>Leukocytes (neutrophilic)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methods</topic><topic>Methotrexate</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Prophylaxis</topic><topic>Radiation</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Siblings</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Survival</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation, Homologous</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>REMBERGER, M</creatorcontrib><creatorcontrib>NASEH, N</creatorcontrib><creatorcontrib>ASCHAN, J</creatorcontrib><creatorcontrib>BARKHOLT, L</creatorcontrib><creatorcontrib>LEBLANC, K</creatorcontrib><creatorcontrib>SVENNBERG, P</creatorcontrib><creatorcontrib>RINGDEN, O</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>REMBERGER, M</au><au>NASEH, N</au><au>ASCHAN, J</au><au>BARKHOLT, L</au><au>LEBLANC, K</au><au>SVENNBERG, P</au><au>RINGDEN, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>32</volume><issue>2</issue><spage>217</spage><epage>223</epage><pages>217-223</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignancies were included. Conditioning consisted of total-body irradiation in 118 and busulphan in 37 patients. They were all given methotrexate combined with cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Of the 155 patients, 66 (43%) received G-CSF after HSCT. Those given G-CSF had a significantly shorter time to neutrophil engraftment (P <0.001). G-CSF treatment had no effect on erythrocyte transfusions, platelet engraftment and infections. However, patients treated with G-CSF had a significantly higher incidence of grades II-IV acute GVHD than those not given this treatment (34 vs 9%, P <0.001). The multivariate analysis showed that the effect of G-CSF was independent of other known risk factors for grades II-IV acute GVHD. Death from GVHD occurred in four and two cases (P=0.06) in the two groups, respectively. The cumulative incidences of transplant-related mortality, survival, chronic GVHD, relapse and relapse-free survival were similar in both groups. In conclusion, G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II-IV acute GVHD, but not transplant-related mortality.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>12838288</pmid><doi>10.1038/sj.bmt.1704108</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2003-07, Vol.32 (2), p.217-223 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_589295 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | Acute Disease Adolescent Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Busulfan Care and treatment Child Child, Preschool Colony-stimulating factor Cyclosporins Donors Erythrocytes Female Graft Survival - drug effects Graft versus host disease Graft versus host reaction Graft vs Host Disease - chemically induced Graft vs Host Disease - mortality Graft vs Host Disease - pathology Granulocyte colony-stimulating factor Granulocyte Colony-Stimulating Factor - adverse effects Granulocyte Colony-Stimulating Factor - therapeutic use Health aspects Hematologic Neoplasms - complications Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - mortality Hematopoietic stem cells Histocompatibility antigen HLA HLA Antigens Humans Incidence Infant Irradiation Leukocytes (granulocytic) Leukocytes (neutrophilic) Male Medical sciences Methods Methotrexate Middle Aged Mortality Multivariate analysis Patients Physiological aspects Prophylaxis Radiation Retrospective Studies Risk analysis Risk factors Siblings Stem cell transplantation Stem cells Survival Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Homologous Transplants & implants |
| title | G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T04%3A11%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=G-CSF%20given%20after%20haematopoietic%20stem%20cell%20transplantation%20using%20HLA-identical%20sibling%20donors%20is%20associated%20to%20a%20higher%20incidence%20of%20acute%20GVHD%20II-IV&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=REMBERGER,%20M&rft.date=2003-07-01&rft.volume=32&rft.issue=2&rft.spage=217&rft.epage=223&rft.pages=217-223&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1704108&rft_dat=%3Cgale_swepu%3EA182430801%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216637406&rft_id=info:pmid/12838288&rft_galeid=A182430801&rfr_iscdi=true |